| 1 |
Zhang L, Wang X, Ming A, Tan W. Pseudotyped Virus for Flaviviridae. Adv Exp Med Biol 2023;1407:313-27. [PMID: 36920705 DOI: 10.1007/978-981-99-0113-5_17] [Reference Citation Analysis]
|
| 2 |
Rafati A, Esmaeili Gouvarchin Ghaleh H, Azarabadi A, Masoudi MR, Afrasiab E, Ghorbani Alvanegh A. Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus. Transpl Immunol 2022;75:101721. [PMID: 36150664 DOI: 10.1016/j.trim.2022.101721] [Reference Citation Analysis]
|
| 3 |
Kumar A, Hossain RA, Yost SA, Bu W, Wang Y, Dearborn AD, Grakoui A, Cohen JI, Marcotrigiano J. Structural insights into hepatitis C virus receptor binding and entry. Nature 2021;598:521-5. [PMID: 34526719 DOI: 10.1038/s41586-021-03913-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 4 |
Liu X, Wang M, Yin X. Cellular Organelles Involved in Hepatitis E Virus Infection. Pathogens 2021;10:1206. [PMID: 34578238 DOI: 10.3390/pathogens10091206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 5 |
Deng L, Hernandez N, Zhong L, Holcomb DD, Yan H, Virata ML, Tarafdar S, Xu Y, He Y, Struble E, Alter HJ, Zhang P. A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization. Proc Natl Acad Sci U S A 2021;118:e2104242118. [PMID: 34260404 DOI: 10.1073/pnas.2104242118] [Reference Citation Analysis]
|
| 6 |
Ghanaat K, Sharafi H, Alavian SM. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urol Mon 2021;13. [DOI: 10.5812/numonthly.114049] [Reference Citation Analysis]
|
| 7 |
Ehtesabi H. Application of carbon nanomaterials in human virus detection. Journal of Science: Advanced Materials and Devices 2020;5:436-50. [DOI: 10.1016/j.jsamd.2020.09.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 8 |
Zarnegar G, Farhadi A, Seyyedi N, Aboualizadeh F, Ranjbaran R, Farzanfar E, Nejabat N, Behzad-behbahani A. In Vitro Replication of HCV RNA in Peripheral Blood Mononuclear Cells Isolated from Patients Undergoing Treatment for Hepatitis C Virus Infection. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.108070] [Reference Citation Analysis]
|
| 9 |
Tzarum N, Giang E, Kadam RU, Chen F, Nagy K, Augestad EH, Velázquez-Moctezuma R, Keck ZY, Hua Y, Stanfield RL, Dreux M, Prentoe J, Foung SKH, Bukh J, Wilson IA, Law M. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci Adv 2020;6:eabb5642. [PMID: 32754640 DOI: 10.1126/sciadv.abb5642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 10 |
Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
|
